SVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Savara Inc. (SVRA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are positive catalysts such as insider buying and an increased price target by analysts, the technical indicators and options data suggest a bearish sentiment in the short term. Additionally, the company's financial performance shows improvement in net income and EPS but remains unprofitable overall. Given the lack of strong trading signals and the current negative price momentum, it is advisable to hold off on investing until clearer positive trends emerge.
The MACD is negative and expanding, indicating bearish momentum. RSI is at 28.403, nearing oversold territory but not yet signaling a reversal. Moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 5.692, with key support at 5.118.
Insider buying has increased significantly by 373.33% over the last month. Analysts have raised the price target to $10, citing potential success with the Molbreevi drug launch.
The stock is down 3.64% in the regular market and 2.91% in pre-market trading. Technical indicators show bearish momentum, and options data reflects a bearish sentiment with a high put-call ratio.
In Q3 2025, net income improved by 21.91% YoY to -$29.56M, and EPS improved by 27.27% YoY to -0.14. However, the company remains unprofitable with no revenue growth.
H.C. Wainwright analyst Andrew Fein raised the price target from $8 to $10 and maintained a Buy rating, citing the company's strong position ahead of the Molbreevi drug launch.
